CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

Zoran Popmihajlov; Donna J Sutherland; Gerald S Horan; Atalanta Ghosh; David A Lynch; Paul W Noble; Luca Richeldi; Theodore F Reiss; Steven Greenberg

doi:10.1136/bmjresp-2021-001060

Article info

Interstitial lung disease

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

Authors

Zoran Popmihajlov Bristol Myers Squibb, Princeton, New Jersey, USA PubMed articles Google scholar articles
Donna J Sutherland Bristol Myers Squibb, Princeton, New Jersey, USA PubMed articles Google scholar articles
Gerald S Horan Bristol Myers Squibb, Princeton, New Jersey, USA PubMed articles Google scholar articles
Atalanta Ghosh Bristol Myers Squibb, Princeton, New Jersey, USA PubMed articles Google scholar articles
David A Lynch Department of Radiology, National Jewish Health, Denver, Colorado, USA PubMed articles Google scholar articles
Paul W Noble Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA PubMed articles Google scholar articles
Luca Richeldi Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli IRCSS, Rome, Italy PubMed articles Google scholar articles
Theodore F Reiss Bristol Myers Squibb, Princeton, New Jersey, USA PubMed articles Google scholar articles
Steven Greenberg Bristol Myers Squibb, Princeton, New Jersey, USADivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, New York, USA PubMed articles Google scholar articles

Correspondence to Zoran Popmihajlov; zoran.popmihajlov{at}bms.com

View Full Text

Citation

Popmihajlov Z, Sutherland DJ, Horan GS, et al

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

BMJ Open Respiratory Research 2022;9:e001060. doi: 10.1136/bmjresp-2021-001060

Publication history

Received July 20, 2021
Accepted December 18, 2021
First published January 20, 2022.

Online issue publication

October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.